

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(See as many sheets as necessary)

Sheet

1

of

1

Complete if Known

Application Number	10/551,298
Filing Date	September 23, 2005
First Named Inventor	Andreas BERGMANN
Art Unit	1641
Examiner Name	Christine E. Foster
Attorney Docket Number	BOEHM-PTO-0043

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		CYR, Melanie, et al., "Bradykinin and Des-Arg ⁹ -bradykinin metabolic pathways and kinetics of activation of human plasma," Am J Physiol Heart Circ Physiol 281:H275-H283, 2001.	
		DOMSCHKE, S., et al., "Vasopeptide intestinal peptide in man: pharmacokinetics, metabolic and circulatory effects," Gut, 1976, 17, 1049-1053.	
		ETO, T., "A review of the biological properties and clinical implications of adrenomedullin and proadrenomedullin N-terminal 20 peptide (PAMP), hypotensive and vasodilating peptides," Peptides 22 (2001) 1693-1711.	
		ETO, T., et al., "Differential Hormonal Profiles of Adrenomedullin and Proadrenomedullin N-Terminal 20 Peptide in Patients with Heart Failure and Effect of Treatment on Their Plasma Levels," Clin. Cardiol. 22, 113-117 (1999).	
		HUNT, P.J., et al., "Bioactivity and Metabolism of C-Type Natriuretic Peptide in Normal Man," J of Clin Endocr and Metab, Vol. 87, No. 6, 1428-1435.	
		JAPP, A.G., et al., "Vasculär Effects of Apelin In Vivo in Man," Journal of the American College of Cardiology (JACC), downloaded from content.onlinejacc.org on April 9, 2011, JACC, Vol. 52, No. 11, 2008, September 9, 2008, 908-913.	
		KIMURA, K., et al., "ANP is cleared much faster than BNP in patients with congestive heart failure," Eur J Clin Pharmacol (2007) 63:699-702.	
		KITAMURA, K., et al., "Identification and hypotensive activity of proadrenomedullin N-terminal 20 peptide (PAMP)," FEBS Letters 351 (1994) 35-37.	
		KRAENZLIN, M.E., et al., "Infusion of a novel peptide, calcitonin gene-related peptide (CGRP) in man. Pharmacokinetics and effects on gastric acid secretion and on gastrointestinal hormones," Regulatory Peptides, 10 (1985) 189-197.	
		LEWIS, L.K., et al., "Adrenomedullin (1-52) measured in human plasma by radioimmunoassay: plasma concentration, adsorption, and storage," Clinical Chemistry 44:3, 571-577 (1998).	
		LUNDBERG, J.M., et al., "Evidence for Release of Endothelin-1 in Pigs and Humans," Journal of Cardiovascular Pharmacology, 17 (Suppl. 7):S350-S353.	
		MAGNESS, R.R., Ph.D., et al., "Angiotensin II metabolic clearance rate and pressor responses in nonpregnant and pregnant women," Am J Obstet Gynecol, Vol. 171, No. 3, 668-679.	
		MEERAN, K., et al., "Circulating adrenomedullin does not regulate systemic blood pressure but increases plasma prolactin after intravenous infusion in humans: a pharmacokinetic study," J Clin Endocrinol Metab, 1997; 82:95-100.	
		STRUCL, J., et al., "Identification of an Adrenomedullin precursor fragment in plasma of sepsis patients," Peptides 25 (2004) 1369-1372.	
		Webster's New World Dictionary (of the American Language), Second College Edition, 1982, p. 1568.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.